Vasopressin Receptor Antagonists

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


Arginine vasopressin (AVP) is the principal hormone involved in regulating the tonicity of body fluids. Less appreciated is the role that AVP plays in a variety of other physiologic functions including glucose metabolism, cardiovascular homeostasis, bone metabolism, and cognitive behavior. AVP receptor antagonists are now available and currently approved to treat hyponatremia. There is a great deal of interest in exploring the potential benefits that these drugs may play in blocking AVP-mediated effects in other organ systems. The purpose of this report is to provide an update on the expanding role of AVP receptor antagonists and what disease states these drugs may eventually be used for.

Original languageEnglish (US)
JournalCurrent hypertension reports
Issue number1
StatePublished - Jan 2015


  • Aquaporin
  • Arginine vasopressin
  • Cirrhosis
  • Congestive heart failure
  • Conivaptan
  • Endolymphatic hydrops
  • Hyponatremia
  • Osteoporosis
  • Polycystic kidney disease
  • Potassium
  • Syndrome of inappropriate antidiuretic hormone secretion (SIADH)
  • Tolvaptan
  • Vasopressin receptor V1a
  • Vasopressin receptor V1b
  • Vasopressin receptor V2

ASJC Scopus subject areas

  • Internal Medicine


Dive into the research topics of 'Vasopressin Receptor Antagonists'. Together they form a unique fingerprint.

Cite this